Home Cart Sign in  
Chemical Structure| 2012607-27-9 Chemical Structure| 2012607-27-9

Structure of WNK463
CAS No.: 2012607-27-9

Chemical Structure| 2012607-27-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

WNK463 is a potant With-No-Lysine (WNK) kinase inhibitor with IC50s of 5/1/6/9 nM for WNK1/2/3/4.

Synonyms: WNK463

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of WNK463

CAS No. :2012607-27-9
Formula : C21H24F3N7O2
M.W : 463.46
SMILES Code : O=C(C1=CN=CN1C2CCN(C3=NC=C(C4=NN=C(C(F)(F)F)O4)C=C3)CC2)NC(C)(C)C
Synonyms :
WNK463
MDL No. :MFCD30489744
InChI Key :HWSHOMMVLGBIDN-UHFFFAOYSA-N
Pubchem ID :121487936

Safety of WNK463

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of WNK463

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CD4+ T cells 2.5 μM 1 h To investigate the role of WNK1 kinase activity in TCR/CD28-induced proliferation of CD4+ T cells, results showed that WNK1 kinase activity is required for TCR/CD28-induced proliferation of CD4+ T cells. PMC11845700
LR73 cells 10 μM 1 h To evaluate the effect of WNK463 on the phagocytosis of apoptotic cells by LR73 cells, results showed that WNK463 treatment enhanced efferocytosis. PMC7140761
bone marrow-derived macrophages 10 μM 1 h To evaluate the effect of WNK463 on the phagocytosis of apoptotic cells by bone marrow-derived macrophages, results showed that WNK463 treatment enhanced efferocytosis. PMC7140761
peritoneal macrophages 10 μM 1 h To evaluate the effect of WNK463 on the phagocytosis of apoptotic cells by peritoneal macrophages, results showed that WNK463 treatment enhanced efferocytosis. PMC7140761
mouse podocytes 0.5 to 20 μM WNK463 reduced phosphorylation of both SPAK and OSR1, indicating that OSR1/SPAK are partially activated by WNK prior to osmotic stimulation. PMC7884762
HEK293T cells 10 μM 2 h Inhibition of WNK kinases, enhancing the catalytic activity of Nedd4-2 PMC9335340
MDCK cells 10 μM 2 h Inhibition of WNK kinases, enhancing the catalytic activity of Nedd4-2 PMC9335340
mpkCCD c14 cells 100 nM 24 h To investigate the effect of WNK463 on TRPV4 activity, results showed that WNK463 significantly reduced TRPV4-dependent Ca2+ influx. PMC8231605
MDA-MB-231 cells 1 μM 24 h WNK463 reduced invasion of MDA-MB-231 cells in collagen matrices PMC9013269
HEK-293 cells 1 µM 30 min ZT-1a inhibited phosphorylation of NKCC1 p-Thr203/207/212 by 72 ± 5.2% PMC6946680
HEK-293 cells 3 µM 30 min ZT-1a inhibited phosphorylation of KCC sites 1/2 by 65–77% PMC6946680
H2009 1 µM 48 h WNK463 significantly increased the death of cancer cells by activated PBMCs PMC9722663
MC38 1 µM 72 h WNK463 reduced PD-L1 expression in MC38 cells PMC9722663

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice RAG1-deficient mice intraperitoneal injection 2 mg 3 consecutive days To investigate the role of WNK1 in T cells, results showed that WNK1-deficient T cells are unable to support a TD antibody response. PMC11845700
mice thymic engulfment model and peritoneal engulfment model intraperitoneal injection 1 mg/kg injected 1 hour before and concurrently with injection of apoptotic cells or dexamethasone, lasting for 12 hours To evaluate the effect of WNK463 on the phagocytosis of apoptotic cells by resident macrophages in mice, results showed that WNK463 treatment enhanced efferocytosis. PMC7140761
Mice C57BL/6 mice Drinking water 1 mg/kg Once daily for 3 days To investigate the effect of WNK463 on TRPV4 activity, results showed that WNK463 significantly reduced TRPV4-dependent Ca2+ influx. PMC8231605
Mice MDA-MB-231 bone metastasis model Oral 1-1.5 mg/kg Daily administration for 4 weeks WNK463 reduced tumor burden and metastasis in mice PMC9013269
mice model of ischemic stroke intraperitoneal injection 5 mg/kg two doses at 3 h and 8 h post reperfusion ZT-1a reduced brain infarct volume and cerebral edema, and improved neurological function PMC6946680
mice MC38 syngeneic colon adenocarcinoma model oral 5 or 10 mg/kg once daily for 9 days WNK463 dose-dependently suppressed tumor growth and increased IFN-γ and TNF-α produced by CD4+ and CD8+ T cells in tumor-infiltrating lymphocytes PMC9722663

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.16mL

0.43mL

0.22mL

10.79mL

2.16mL

1.08mL

21.58mL

4.32mL

2.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories